Compare Medicure, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0.78%
- The company has been able to generate a Return on Equity (avg) of 0.78% signifying low profitability per unit of shareholders funds
2
Flat results in Mar 26
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CAD 11 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.09
-53.75%
0.86
Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Mar 2026)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
26.32%
0%
26.32%
6 Months
-4.0%
0%
-4.0%
1 Year
3.45%
0%
3.45%
2 Years
10.09%
0%
10.09%
3 Years
3.45%
0%
3.45%
4 Years
0%
0%
0.0%
5 Years
3.45%
0%
3.45%
Medicure, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.26%
EBIT Growth (5y)
0.50%
EBIT to Interest (avg)
-2.20
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
1.36
Tax Ratio
17.29%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
1.01%
ROE (avg)
0.78%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.86
EV to EBIT
-1.48
EV to EBITDA
-2.47
EV to Capital Employed
0.84
EV to Sales
0.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-56.99%
ROE (Latest)
-53.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : May 2014
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
7.90
8.50
-7.06%
Operating Profit (PBDIT) excl Other Income
0.30
-3.50
108.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.40
-4.20
90.48%
Operating Profit Margin (Excl OI)
-46.20%
-494.40%
44.82%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -7.06% vs 3.66% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 90.48% vs -200.00% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
28.90
21.90
31.96%
Operating Profit (PBDIT) excl Other Income
-4.20
-0.40
-950.00%
Interest
0.00
0.00
Exceptional Items
0.00
1.90
-100.00%
Consolidate Net Profit
-7.10
-1.00
-610.00%
Operating Profit Margin (Excl OI)
-238.70%
-124.90%
-11.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 31.96% vs 0.92% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -610.00% vs -11.11% in Dec 2024
About Medicure, Inc. 
Medicure, Inc.
Pharmaceuticals & Biotechnology
Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Company Coordinates 
Company Details
1250 Waverley St Suite 2 , WINNIPEG MB : R3T 6C6
Registrar Details






